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Double-stranded DNA induces a 
prothrombotic phenotype in the 
vascular endothelium
Erik Gaitzsch1,2, Thomas Czermak3, Andrea Ribeiro1, Yvonn Heun4, Monica Bohmer4, Monika 
Merkle1, Hanna Mannell4, Christian Schulz  3,5, Markus Wörnle1 & Joachim Pircher3,5
Double-stranded DNA (dsDNA) constitutes a potent activator of innate immunity, given its ability 
to bind intracellular pattern recognition receptors during viral infections or sterile tissue damage. 
While effects of dsDNA in immune cells have been extensively studied, dsDNA signalling and its 
pathophysiological implications in non-immune cells, such as the vascular endothelium, remain 
poorly understood. The aim of this study was to characterize prothrombotic effects of dsDNA in 
vascular endothelial cells. Transfection of cultured human endothelial cells with the synthetic dsDNA 
poly(dA:dT) induced upregulation of the prothrombotic molecules tissue factor and PAI-1, resulting 
in accelerated blood clotting in vitro, which was partly dependent on RIG-I signalling. Prothrombotic 
effects were also observed upon transfection of endothelial cells with hepatitis B virus DNA-containing 
immunoprecipitates as well human genomic DNA. In addition, dsDNA led to surface expression of von 
Willebrand factor resulting in increased platelet-endothelium-interactions under flow. Eventually, 
intrascrotal injection of dsDNA resulted in accelerated thrombus formation upon light/dye-induced 
endothelial injury in mouse cremaster arterioles and venules in vivo. In conclusion, we show that viral 
or endogenous dsDNA induces a prothrombotic phenotype in the vascular endothelium. These findings 
represent a novel link between pathogen- and danger-associated patterns within innate immunity and 
thrombosis.
The innate immune system constitutes a key response to both invading pathogens and sterile injury by recognition 
of pathogen associated- or danger associated molecular patterns (PAMPs or DAMPs, respectively). In this con-
text lipopolysaccharides (LPS), peptidoglycans, high-mobility group protein-1 (HMGB1), double stranded DNA 
(dsDNA) and others are released into the circulation1–3. dsDNA is a powerful activator of the innate immune 
system4 and acts via several so called pattern-recognition receptors such as TLR-9 (toll-like receptor 9), AIM2 
(absent in melanoma 2), DAI (DNA-dependent activator of IRFs), RIG-I (after transformation of DNA by RNA 
polymerase III)4, 5, and most recently Interferon-γ-inducible protein16 (IFI16) and cGAMP synthase (cGAS) have 
been discovered and shown to recognize intracellular dsDNA6. While the dsDNA-mediated immune response 
has been extensively studied in immune cells, little is known so far about the pathophysiological relevance of 
dsDNA for the vascular endothelium.
dsDNA plays a central role in viral infections such as hepatitis B, which often manifest as systemic diseases 
involving several organs including the vascular system. Morbidity and mortality result in part from vasculitis7, 8 
but also from thrombotic complications including fatal thrombo-embolic events, such as myocardial infarction 
and ischemic stroke9, 10. Moreover viral infections are likely to play a role in the pathophysiology of atheroscle-
rosis11. Even though not primarily considered part of the immune system, the endothelium as the inner layer of 
blood vessels plays a major role in host defense constituting an anatomical and functional barrier for pathogens to 
invade tissues. Additionally, the endothelium has essential function in suppressing inflammation and thrombosis 
by controlling vascular tone and function12. Endothelial inflammation leads to disruption of the haemostatic bal-
ance towards a prothrombotic state with increased risk of thrombo-embolic events13. Activated ECs are known 
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to facilitate blood coagulation by down-regulation of antithrombotic proteins, such as thrombomodulin, tissue 
plasminogen activator or endothelial protein C receptor and by increased expression of procoagulant proteins 
such as the antifibrinolytic plasminogen activator inhibitor-1 (PAI-1) or tissue factor (TF)14.
We and others have previously shown, that the vascular endothelium is able to sense intracellular dsDNA and 
can exert a strong inflammatory response15, 16. In this study we investigated prothrombotic effects of dsDNA in 
the vascular endothelium.
Results
Double-stranded DNA led to nuclear translocation of transcription factors IRF3 and 
NF-κB. Human microvascular endothelial cells (HMEC) were treated with poly(dA:dT) 5 µg/mL with 
or without complexation with cationic lipids (Lipofectamine 2000) for 6 hours and stained with DAPI and 
anti-Lamin-antibody. Only poly(dA:dT) complexed with cationic lipids but not poly(dA:dT) alone led to uptake 
of dsDNA into the intracellular compartments (representative images in Fig. 1a). Transfection of endothelial cells 
with poly(dA:dT) led to nuclear translocation of transcription factors IRF3 and to a lesser extent of NF-κB as 
shown by immunofluorescent staining (representative images in Fig. 1b and c). To check integrity of the endothe-
lial cell monolayer 8 hours after transfection with poly(dA:dT) bright field images were taken, which showed 
comparable intact monolayers in cells treated with poly(dA:dT) with or without cationic lipids (representative 
images in Fig. 1d).
Double-stranded DNA induces expression of prothrombotic genes in vascular endothelial 
cells. Next, we measured expression of pro- and antithrombotic genes by real-time PCR. Transfection of 
human microvascular endothelial cells (HMEC) with poly(dA:dT) (5 µg/mL) induced time-dependent expres-
sion of tissue factor as well as plasminogen activator inhibitor-1 (PAI-1) with a maximal relative increase at 6 
or 12 hours, respectively (Fig. 2a and b). We also observe significantly increased expression of the fibrinolytic 
molecule tissue plasminogen activator (tPA) after 6 hours of cell transfection with poly(dA:dT) (Fig. 2c), while 
thrombomodulin (THBD) expression was slightly increased after 6 hours of transfection with poly(dA:dT) after 
an initial decrease after 3 hours (Fig. 2d).
Double stranded DNA induced prothrombotic proteins and accelerates endothelial dependent 
blood clotting in vitro. Next, upregulation of prothrombotic molecules tissue factor and PAI-1 was assessed 
on protein level. Tissue factor surface expression on the cell membrane was significantly increased after stimula-
tion with poly(dA:dT) for 12 hours as assessed by flow cytometry (Fig. 3a). PAI-1 release by endothelial cells as 
measured by ELISA was significantly increased 12 hours after transfection with poly(dA:dT) but not after 6 hours 
as compared to respective time-matched controls. In contrast, PAI-1 release was not influenced after stimulation 
of endothelial cells with poly(dA:dT) alone, i.e. without cationic lipids (Fig. 3b).
In order to functionally analyze prothrombotic properties of endothelial cells, an endothelial dependent blood 
clotting assay was performed. Lysates of poly(dA:dT) transfected endothelial cells accelerated blood clotting time 
compared to time-matched control cells (Fig. 3c, left). Stimulation of whole blood with lysates of endothelial 
cells treated with poly(dA:dT) alone (i.e. without cationic lipids) had no effect on blood clotting time (Fig. 3c, 
right). Similar to cells transfected with the synthetic dsDNA analogue poly(dA:dT), lysates of endothelial cells 
transfected with human genomic DNA from peripheral human leukocytes also induced a significantly accelerated 
blood clotting compared to control cells after 12 hours (Fig. 3e). The prothrombotic effect of poly(dA:dT) after 
12 hours was partly reversed after prior transfection of endothelial cells with siRNA silencing RIG-I receptor 
(Fig. 3d).
Double stranded DNA induces vWF upregulation and platelet tethering in vitro. Von Willebrand 
factor (vWF) surface expression and platelet adhesion were analyzed in primary human umbilical vein endothe-
lial cells (HUVEC). Transfection of endothelial cells with poly(dA:dT) significantly increased surface expression 
of vWF after 12 hours as assessed by flow cytometry (Fig. 4a). To investigate the functional relevance of this obser-
vation, interactions between endothelial cells and platelets were examined in a model of static adhesion. Therefore 
endothelial cells pre-treated with poly(dA:dT) for 12 hours were then co-cultivated with freshly isolated platelets 
from healthy volunteers for 6 hours. Endothelial cells transfected with dsDNA showed significantly increased 
numbers of adherent platelets as compared to non-stimulated cells (Fig. 4b). In order to confirm our findings 
in a more physiological setting, we established a flow based assay of platelet endothelium interaction. Therefore 
freshly isolated human platelets were labeled with Calcein and flushed over cultured endothelial cells in a flow 
chamber simulating a vascular shear stress of 1 dyn/cm2 and platelet-endothelial cell interactions were analyzed 
by immunofluorescence microscopy (Fig. 4c). Poly(dA:dT) transfected endothelial cells showed significantly 
increased amount of tethering platelets compared to non stimulated cells (Fig. 4d). Additionally the number of 
very slow rolling platelets was higher on poly(dA:dT) transfected endothelial cells, however (considering the high 
number of overall transfused platelets) the median velocity of platelets was not different in both groups (Fig. 4e).
Double stranded DNA accelerates microvascular thrombosis in vivo. To investigate the effects of 
double stranded DNA on thrombus formation in vivo, 10 μg poly(dA:dT) complexed with 10 μl of Lipofectamine 
or transfection reagent alone (control group) was injected into the scrotum of C57Bl/6 mice. Intravital micros-
copy of cremaster muscle vessels was performed 12 hours after injection and thrombus formation was induced 
by light/dye-injury after injection of FITC-labeled dextran. Vessel diameters did not differ significantly between 
both groups and were 53 +/− 5 µm vs. 48 +/− 6 µm in venules and 51 +/− 9 µm vs. 50 +/− 3 µm in arterioles 
control treated vs. dsDNA treated animals respectively. dsDNA stimulation significantly accelerated thrombus 
formation in vivo resulting in a reduced time until onset of thrombus formation after injury in arterioles (Fig. 5c) 
www.nature.com/scientificreports/
3Scientific RepoRts | 7: 1112  | DOI:10.1038/s41598-017-01148-x
Figure 1. Double-stranded DNA led to nuclear translocation of transcription factors IRF3 and NF-κB. (a) 
Immunofluorescent staining of cultured endothelial cells with DAPI (blue) and anti-Lamin-antibody (red) 
showed transfection of poly(dA:dT) into the intracellular compartment after complex formation with cationic 
lipids. Scale bar is 10 µm. (b,c) Transfection of endothelial cells with poly(dA:dT) led to nuclear translocation 
of transcription factors IRF3 (b) and to a lesser extent of NF-κB (c). Cells were stained with antibodies against 
IRF3 (green) and p65-subunit of NF-κB (red). Scale bar is 10 µm. (d) Representative bright field images upon 
treatment of endothelial cells with poly(dA:dT) with or without cationic lipids. Scale bar is 100 µm.
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and eventually also in significantly reduced time until complete thrombotic vessel occlusion with flow cessation 
in both venules and arterioles (Fig. 5a and b, representative images in Fig. 5e).
Hepatitis B virus DNA-containing immunoprecipitates induce a prothrombotic phenotype. To 
translate our findings into a clinical context we investigated whether Hepatitis B virus DNA induces prothrom-
botic effects in the vascular endothelium. Therefore we transfected microvascular endothelial cells with hepa-
titis B virus (HBV)-containing immunoprecipitates, that were collected during plasmapheresis from a patient 
with HBV-associated polyarteritis nodosa. Similar to transfection with the synthetic analogue poly(dA:dT) 
HBV-containing immunoprecipitates exerted a prothrombotic phenotype in transfected endothelial cells 
resulting in upregulation of tissue factor already after 3 hours and upregulation of PAI-1 expression after 10 h as 
assessed by real-time PCR (Fig. 5a and b respectively, left images). HBV-DNA alone (i.e. without cationic lipids) 
had no effect on expression of tissue factor and PAI-1 expression compared to time-matched controls (Fig. 6a and 
b, respectively, right images).
Discussion
In this study, we show direct prothrombotic effects of intracellular double stranded DNA (dsDNA) in the vascular 
endothelium. dsDNA led to upregulation of the procoagulatory proteins tissue factor and PAI-1 and increased 
surface expression of vWF and eventually resulted in accelerated blood clotting in vitro and thrombus formation 
in a model of endothelial injury in vivo. Similar effects were observed after transfection of endothelial cells with 
hepatitis B virus DNA containing immunoprecipitates and with endogenous human DNA.
In previous work we showed that dsDNA, both from viral origin as well as endogenous DNA, can induce 
pro-inflammatory effects in endothelial cells resulting in upregulation of inflammatory cytokines such as IL-6, 
IL-8, MCP-1, RANTES, IP-10 and IFN-β, as well as the adhesion molecules ICAM-1 and VCAM-1 on human 
endothelial cells15. Furthermore, dsDNA has been described to induce TNFα release from endothelial cells and 
thereby promoting leukocyte adhesion16. Similar effects have also been observed in glomerular endothelial cells 
where dsDNA functionally increased albumin permeability17.
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Figure 2. Double-stranded DNA induces expression of prothrombotic genes in vascular endothelial cells. (a,b) 
Expression of the prothrombotic molecules tissue factor (a) and Plasminogen activator inhibitor-1 (PAI-1, b) 
as assessed by RT-PCR upon transfection of vascular endothelial cells with poly(dA:dT). (c,d) Expression of 
the antithrombotic molecules tissue plasminogen activator (tPA, (c)) and thrombomodulin (THBD, (d)) upon 
transfection of vascular endothelial cells with poly(dA:dT); (*P < 0.05 vs. respective time-matched control, 
n = 4).
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Figure 3. Double stranded DNA induces prothrombotic proteins and accelerates endothelial dependent 
blood clotting in vitro. (a) Tissue factor surface expression was assessed by flow cytometry 12 hours after 
transfection of endothelial cells with poly(dA:dT) (*P < 0.05 vs. control, n = 8, MFI mean fluorescence 
intensity). Representative histogram is shown on the right. (b) PAI-1 release by endothelial cells was measured 
by ELISA 6 and 12 hours after transfection with poly(dA:dT), PAI-1 release after stimulation of endothelial cells 
with poly(dA:dT) alone (i.e. without cationic lipids) is shown on the right (*P < 0.05 vs. time matched control, 
n = 5). (c) Stimulation of whole blood with endothelial cell lysates transfected with poly(dA:dT) accelerated 
blood clotting time compared to stimulation with untreated cell lysates as measured by thromboelastometry. 
Stimulation of whole blood with lysates of endothelial cells treated with poly(dA:dT) alone (i.e. without 
cationic lipids) had no effect on blood clotting time (right) (*P < 0.05 vs. time matched control, n = 4). (d) The 
prothrombotic effect of poly(dA:dT) after 12 hours was partly reversed by siRNA-silencing of RIG-I (*P < 0.05 
vs. time matched control, n = 4). (e) A similar prothrombotic effect was observed 12 hours after transfection of 
endothelial cells with human genomic DNA (*P < 0.05 vs. time-matched control, n = 4).
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Figure 4. Double-stranded DNA induces vWF upregulation and platelet tethering in vitro. (a) Transfection of 
endothelial cells with poly(dA:dT) for 12 hours caused upregulation of von Willebrand factor on the endothelial 
cell surface (*P < 0.05 vs. control, n = 6; MFI mean fluorescence intensity). Representative histogram is 
shown on the right. (b) Co-cultivation of endothelial cells transfected with poly(dA:dT) for 12 hours and non-
stimulated isolated platelets resulted in increased adhesion of platelets to endothelial cells, as assessed by FACS 
analysis (*P < 0.05, vs. control, n = 6). Representative histograms are shown on the right. (c) Representative 
snap shots of flow chamber assays with transfusion of fluorescently labeled platelets simulating vascular shear 
stress of 1 dyn/cm2. Platelet tethering (white arrow) and very slow rolling platelets (white arrowhead) were 
analyzed after stimulation of endothelial cells with poly(dA:dT) for 12 hours. (d) Quantitative analysis showed 
increased number of tethering platelets (*P < 0.05 vs. control, n = 9) as well as (e) increased number of very 
slow rolling platelets (as displayed by the black columns in the histograms showing platelet velocity profiles) 
upon transfection with poly(dA:dT).
www.nature.com/scientificreports/
7Scientific RepoRts | 7: 1112  | DOI:10.1038/s41598-017-01148-x
a b
O
ns
et
 o
f t
hr
om
bu
s 
fo
rm
at
io
n 
(m
in
ut
es
)
0
5
10
15
20
*
c d
O
ns
et
 o
f t
hr
om
bu
s 
fo
rm
at
io
n 
(m
in
ut
es
)
0
5
10
15
20
25
30
35
40
45
50
Ti
m
e 
to
 v
es
se
l o
cc
lu
si
on
 (m
in
ut
es
)
0
2
4
6
8
10
12
14
*
0
5
10
15
20
25
30
35
40
45
50
Ti
m
e 
to
 v
es
se
l o
cc
lu
si
on
 (m
in
ut
es
)
*
CL CL + dsDNA
Ar
te
rio
le
Ve
nu
le
e
Venules Venules
Arterioles Arterioles
CL CL + dsDNA CL CL + dsDNA
CL CL + dsDNA CL CL + dsDNA
Figure 5. Double-stranded DNA accelerates microvascular thrombosis in vivo. Thrombus formation in vivo 
was investigated by phototoxic (light/dye-induced) vessel injury of microvessels in the mouse cremaster muscle. 
Intrascrotal injection of poly(dA:dT) (5 µg DNA 12 hours prior to the experiment) resulted in a more rapid 
onset of thrombus formation in arterioles (a) but not in venules (c). Time to complete vessel occlusion was 
significantly accelerated after poly(dA:dT) injection in both arterioles (b) and venules (d). (e) Representative 
images show thrombus formation in mouse cremaster arterioles (20 min after start of injury) and mouse 
cremaster venules (10 min after start of injury) with markedly increased thrombus formation in poly(dA:dT) 
treated animals (right pictures) as compared to control animals (left pictures). Scale bar is 50 µm. (*P < 0.05 vs. 
control, n = 6 animals each).
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In this study we show intracellular dsDNA leads to upregulation of tissue factor, a crucial protein in the acti-
vation of the extrinsic pathway of the coagulation cascade18. Tissue factor initiates the extrinsic pathway of the 
coagulation cascade and contributes to thrombus growth and stabilization19. Additionally, under certain patho-
physiological conditions such as sickle cell disease or antiphospholipid syndrome tissue factor-positive endothe-
lial microparticles have been observed, that can be recruited to the sites of vascular injury and contribute to 
increased thrombin generation20, 21. Physiologically resting endothelial cells express, if at all, very little amounts 
of tissue factor, however, the protein is upregulated under inflammatory conditions14, 22–24. Indeed, on a functional 
level we observed, that stimulation of endothelial cells with dsDNA resulted in accelerated blood clot formation in 
an endothelial-dependent in vitro whole blood clotting assay, which has been shown to be, at least in part, tissue 
factor dependent25.
dsDNA furthermore induced expression of plasminogen activator inhibitor-1 (PAI-1), which is the major 
physiologic inhibitor of tissue-type plasminogen activator in plasma and thereby serves as an endogenous mech-
anism to prevent intravasal thrombosis26. PAI-1 levels are elevated in many diseases associated with increased 
risk of ischemic cardiovascular events27, 28 and have recently been shown to be relevant cardiovascular events in 
chronic hepatitis C infections29.
Interestingly, we also observed changes in antithrombotic molecules. While thrombomodulin expression 
seems to be less influenced by intracellular dsDNA, we observe an upregulation of the fibrinolytic molecule tPA 
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Figure 6. Hepatitis B virus DNA-containing immunoprecipitates induce a prothrombotic phenotype. 
Endothelial cells were transfected with HBV-DNA containing immunoprecipitates isolated from a patient with 
ongoing hepatitis B infection and associated polyarteritis nodosa with a high viral load. HBV-DNA containing 
immunoprecipitates resulted in upregulation of tissue factor starting 3 hours after transfection (a) as well as 
PAI-I at 10 hours after transfection (b) as analyzed by RT-PCR. Expression of tissue factor and PAI-1 after 
stimulation of endothelial cells with HBV-DNA alone (i.e. without cationic lipids) is shown on the right ((a and 
b), respectively). (*P < 0.05 vs. control).
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at certain time points, indicating compensatory mechanisms. However, in our functional experiments dsDNA 
shows an overall prothrombotic effect, which could be explained by a relative stronger expression of the pro-
thrombotic or antifibrinolytic molecules such as PAI-1, a strong prothrombotic counterpart to tPA14.
Several molecular mechanisms seem to be involved in dsDNA signaling in endothelial cells. Consistent with 
findings of previous studies in similar cells we found intracellular dsDNA to induce nuclear translocation of the 
transcription factor IRF3 and to lesser extent also NF-κB16. These transcription factors can upregulate proin-
flammatory and prothrombotic genes. The list of possible receptors being involved in the intracellular sensing 
of dsDNA is long and further expanding4–6. Several of these receptors including AIM2, DAI, TLR9 or RIG-I 
are expressed in endothelial cells and intracellular dsDNA signaling is likely dependent on more than a single 
receptor and pathway30. In a previous study by our group we could see that upregulation of some inflammatory 
markers is dependent on TLR9 signaling15. Considering the slighter prothrombotic effect of dsDNA after trans-
fection of endothelial cells with siRNA and dsDNA, it was partly reversed with siRNA silencing RIG-I receptor, 
indicating this receptor to be relevant for prothrombotic effects.
Besides pro-coagulatory effects, dsDNA in endothelial cells induced surface expression of 
von-Willebrand-factor (vWF) which can bind GPIb-receptor on platelets resulting in platelet-endothelium 
interactions. Indeed, platelet-endothelial cell-aggregates were significantly increased after prior stimulation of 
endothelial cells with dsDNA. Moreover, transfection of primary human endothelial cells cultivated in flow cham-
bers led to increased platelet tethering under dynamic conditions. Platelet-endothelial interactions via vWF-GPIb 
or CD40-CD40L, even when remaining transient, have been shown to further activate the endothelium and 
thereby increase inflammatory effects resulting in thrombosis but also acceleration in development of atheroscle-
rotic lesions31, 32.
Eventually, dsDNA stimulation led to increased thrombus formation upon light/dye-induced endothelial 
injury in mouse cremaster vessels in vivo. In this model the endothelium is not immediately disrupted, such as 
in the case of ferric chloride based injury models, but gradually exposed to increasing oxidative stress. Thus, in 
vitro observed effects of dsDNA are likely to contribute to the prothrombotic effects. However, additional effects 
including expression of other endothelial cell surface molecules, such as inflammatory adhesion molecules (e.g. 
ICAM-1, VCAM-1) or P-Selectin, but also redistribution or interplay between surface molecules may foster pro-
thrombotic effects. Furthermore, other mechanisms such as modulation of endothelial miRNA expression, e.g. 
miR-126 might influence endothelial injury and consecutive vascular thrombosis33. While accelerated complete 
thrombotic vessel occlusion was consistent in arterioles and venules, the onset of thrombus formation was accel-
erated only in arterioles. Among the differences between mechanisms contributing to thrombosis in arterioles 
and venules lower shear rates as well as a considerable role of leukocytes in venules are the most important ones. 
vWF is particularly important for platelet adhesion at higher shear rates, which could explain significant differ-
ences in the onset of thrombus formation in arterioles but not in venules. Notably we observed increased surface 
expression of vWF in vitro upon stimulation of dsDNA which would support this hypothesis.
Poly (dA:dT) when transfected into cells mimics effects of viral DNA and has been used as an analog for viral 
DNA in previous studies by ourselves and others15–17. Viral infections, such as hepatitis B are often associated 
with vasculitis and subsequently thromboembolic complications7, 8, 34. We therefore used immunoprecipitates 
isolated from a patient with ongoing hepatitis B infection and associated systemic vasculitis, to stimulate primary 
endothelial cells. Indeed, with regard to slight differences in the kinetics, we do see a similar upregulation of pro-
thrombotic genes as compared with synthetic dsDNA stimulation, suggesting a putative role of dsDNA triggered 
endothelial activation in viral infections. Our observations could help to elucidate the so far incompletely under-
stood relation between viral infections and atherothrombotic diseases.
Apart from viral infections, dsDNA can be released into the bloodstream from damaged host cells in the con-
text autoimmune diseases, tumor lysis or formation of neutrophil extracellular traps (NETs). We have previously 
shown that human genomic dsDNA can enter the intracellular compartment of endothelial cells under certain 
circumstances and induce an inflammatory response15. In this study we demonstrate that transfection of cul-
tured endothelial cells with human genomic dsDNA accelerates blood clotting in vitro. The induced phenotype is 
therefore similar to the one observed after poly(dA:dT) treatment, however the extent of the prothrombotic effect 
observed was less pronounced as compared to stimulation with poly(dA:dT). This prothrombotic phenotype 
might thereby contribute to thrombo-embolic complications in inflammatory autoimmune disorders that are well 
known to be associated with an increased risk of atherothrombotic events35–37.
In conclusion we could show for the first time a direct pathophysiological role of viral as well as genomic 
intracellular dsDNA in thrombosis and haemostasis by endothelial mediated mechanisms. Our results are in line 
with the growing evidence, that non-primary immune cells, such as endothelial cells, play an important role in the 
recognition and reaction to pathogen- and danger associated molecular patterns within the innate immune sys-
tem. Ultimately, our findings represent a novel link in the increasingly recognized reciprocal connection between 
innate immunity and thrombotic disorders and therefore could be relevant for therapeutic decisions in patients 
with inflammatory and cardiovascular diseases.
Materials and Methods
Chemicals and Antibodies. Poly(dA:dT) was from Invivogen (Toulouse, France), human genomic DNA 
was from AMS Biotechnology (Milton Park, UK), Lipofectamine 2000 transfection agent was from Invitrogen 
(Carlsbad, USA), Accutase was from PAA (Cölbe, Germany), p65-NF-kB antibody and rabbit IRF3 antibody 
were from (Cell Signaling Technology, USA), goat lamin A/C antibody was from Santa Cruz Biotechnology 
(USA). DAPI, Alexa Fluor 488 Chicken Anti-Rabbit IgG, Alexa Fluor 546 Donkey Anti-goat IgG were all from 
Invitrogen (UK). Predesigned TaqMan primers for tissue factor, PAI-1, tPA, thrombomodulin and GAPDH were 
from Applied Biosystems (Carlsbad, California, USA), PAI-1 ELISA-Kit was from Abcam (UK), RIG-I-siRNA 
and negative control siRNA was from Ambion/ThermoFisher (USA). Calcein-AM was from Merck-Millipore 
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(Darmstadt, Germany), anti-human tissue factor-FITC- and anti-human vWF-FITC-antibodies and respective 
isotype-controls were from AbD Serotec (Oxford, UK), anti-human CD41-APC-antibody was from BD (USA). 
All other chemicals unless otherwise indicated in the method section were from Sigma Aldrich (Taufkirchen, 
Germany).
Isolation of hepatitis B virus-DNA (HBV-DNA) containing immunoprecipitates. HBV-DNA 
containing immunoprecipitates were isolated from a patient with a hepatitis B associated polyarteritis nodosa 
with a high viral load, during routine plasmapheresis treatment as described previously15. The concentration of 
HBV-DNA used for stimulation was 2.1 × 106 geq/mL as confirmed by real-time-PCR. Written informed consent 
for the collection of plasma samples was obtained and the procedure was approved by the university ethics review 
board.
Cell culture and stimulation of endothelial cells. Human microvascular endothelial cells (HMEC) 
were provided by Ades et al.38, human umbilical vein endothelial cells (HUVECs) were isolated and cultivated 
as described previously23. Briefly, cells were cultured in M199 media supplemented with 10% fetal calf serum, 
10% endothelial growth media (PromoCell, Heidelberg, Germany), and 1% penicillin/streptomycin. The pro-
cedure was approved by the university ethics review board. dsDNA stimulation was performed as previously 
described [5]. Briefly, 5 µg/mL poly(dA:dT), or for indicated experiments 5 µg/mL human genomic DNA or 
HBV-DNA containing immunoprecipitates were complexed with 1 µl of Lipofectamine 2000 in order to achieve 
intracellular transfection with dsDNA. For stimulation with HBV-containing immunoprecipitates, culture dishes 
with endothelial cells were additionally centrifuged at 1000 g for 45 min after addition of the immunoprecipi-
tates in order to increase efficiency of viral infection. siRNA knockdown of RIG-I was performed as described 
previously15.
Immunofluorescence microscopy. For immunofluorescence experiments, HMEC were grown to con-
fluence in 8-well microscope µ-slides (Ibidi, Germany) and stained as previously described39. After treatment of 
cells as indicated cells were washed with PBS followed by fixation and permeabilization in 100% methanol or for 
30 min. Fixed cells were washed again with PBS and blocked with 5% BSA in PBS for 1 h at room temperature. 
Cells were then incubated with first antibodies diluted 1:200 in blocking solution (goat lamin A/C antibody, 
mouse p65-NF-kB antibody, rabbit IRF3 antibody) for one hour at room temperature. Afterwards, cells were 
washed three times with PBS and subsequently incubated with the secondary antibody diluted 1:400 in blocking 
solution (Alexa Fluor 488 Chicken Anti-Rabbit IgG and Alexa Fluor 546 Donkey Anti-goat IgG) and with DAPI 
for 30 min. Cells were washed and kept in PBS for microscopy. Images were taken with an Axiovert 200 M micro-
scope with ApoTome (Zeiss, Jena, Germany).
Real-time PCR. RNA isolation from endothelial cells and real-time polymerase chain reaction (PCR) were 
performed as described previously23. Commercially available pre-developed TaqMan reagents were used for the 
human target genes PAI-1, Tissue factor, tPA and thrombomodulin. GAPDH was used as reference housekeeping 
gene.
Flow cytometry. Tissue factor and von Willebrand factor were measured on endothelial cell surface by flow 
cytometry. Endothelial cells after indicated stimulation were washed and detached from dishes using accutase and 
stained with fluorescent antibodies or respective isotype controls for 30 minutes at 37 °C. Analysis was performed 
using a FACS Canto II flow cytometer (BD, USA).
ELISA. PAI-1 protein levels were measured in supernatants of cultured endothelial cells after indicated treat-
ments by ELISA according to the manufacturer’s protocol.
Blood donors. All blood donors were healthy volunteers, who had given written consent and had not 
taken any medications for at least 10 days. The investigation was carried out according to the principles of the 
Helsinki-Declaration.
Endothelial-dependent blood clotting assay. Endothelial cells were stimulated as indicated and 
then lysed with 15 mM n-octyl-D-glycopyranosidase in 0.1 M imidazol buffer; 20 μL of cell lysate and 20 μL 
of 200 mmol/L CaCl2 for re-calcification were added to 300 μL of citrated (3.13% sodium citrate) human 
whole blood from healthy volunteers, and clotting time was measured by thromboelastometry (ROTEG; Tem 
Innovations, Munich, Germany).
Platelet preparation. Platelet isolation was performed as previously described40. Platelet rich plasma was 
obtained by centrifugation of anticoagulated (3.13% sodium citrate) whole blood at 340 g for 15 minutes. After 
another centrifugation step at 600 g for 10 minutes in the presence of 2 ng/mL Prostaglandin, platelets were 
washed and resuspended in calcium-free modified Tyrode buffer (138 mmol/L NaCl, 2.7 mmol/L KCl, 12 mmol/L 
NaHCO3, 400 mmol/L Na2HPO4, 1 mmol/L MgCl2, 5 mmol/L D-glucose, and 5 mmol/L HEPES) and adjusted 
to the concentration required for the respective experiment. Platelet counts were obtained using a resistance par-
ticle counter (Coulter Z2, Beckman Coulter, Krefeld, Germany).
Platelet-endothelial cell-aggregates. Endothelial were cultivated and stimulated as indicated. After 
removing the transfection medium and several washing steps with PBS isolated washed platelets from healthy 
donors (prepared as described above) were co-cultivated with endothelial cells for 6 hours. Cells were then 
washed with PBS in order to remove non-adherent platelets and detached with accutase. Platelet-endothelial 
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cell-aggregates were measured by staining with anti-human CD41-APC antibody and quantified by flow 
cytometry.
Flow chamber assay. Endothelial cells were cultivated and stimulated as indicated in a µ-slide from IBIDI 
(Martinsried, Germany). Freshly isolated human platelets were labeled with Calcein (10 µM for 30 min) and per-
fused over the cultured endothelial cells at a shear rate of 1 dyn/cm2. Live immune-fluorescence imaging was 
performed using a Zeiss Axiotech Vario microscope (Carl Zeiss, Oberkochen, Germany). Images were recorded 
with a digital camera (AxioCam HSm; Carl Zeiss). From the resulting length of the platelet trace in single images, 
velocities of single platelets were calculated by using the exposure time of each single picture. Platelet-endothelial 
cell-interaction was expressed by analysis of the amount of tethering platelets (platelets not moving in at least one 
single picture) as well as by analysis of frequency histograms consisting of all platelet velocities.
Animals. Animal experiments were performed in wildtype C57Bl/6 mice, which were purchased from Charles 
River (Sulzfeld, Germany). Surgical procedures were performed under short-term anesthesia induced by a sin-
gle intraperitoneal injection of Midazolam 5 mg/kg (Ratiopharm, Germany), Fentanyl 0.05 mg/kg (CuraMED 
Pharma, Germany), and Medetomidinehydrochloride 0.5 mg/kg (Pfizer, Germany; produced by Orion Pharma, 
Finland) diluted in 0.9% NaCl. All experiments were conducted in accordance with the German animal protec-
tion law and approved by the district government of Upper Bavaria. The investigation conforms to the Directive 
2010/63/EU of the European Parliament.
Intravital assessment of microvascular thrombosis. Microvascular thrombosis in vivo was inves-
tigated in arterioles and venules of the mouse cremaster muscle using a light/dye-injury model as previously 
described41, 42. After anesthesia all surgical procedures were conducted on a thermo-controlled plexi-glass stage 
to maintain body temperature at 37 °C with cover slips for microscopy. Intravital fluorescence microscopy was 
performed using a modified microscope (Zeiss Axiotech Vario, Carl Zeiss Microscopy GmbH, Germany). Images 
were recorded with a digital camera (AxioCam HSm, Carl Zeiss Germany) and analyzed with “AxioVision” (Carl 
Zeiss Microscopy GmbH, Germany). After the surgical preparation of the cremaster muscle 1–2 arterioles and 
1–2 venules per cremaster with a diameter of around 50 μm were chosen and FITC-dextran (average molecular 
weight 150,000 (Sigma-Aldrich, Germany)) in a concentration of 5% in PBS was given in a dose of 1 μl/g mouse 
via a tail vein catheter. Light with a wave length of 450–490 nm was used to excite the fluorescent dye inducing 
photochemical injury of the endothelial cell layer. Two end points were defined, first the onset of thrombus for-
mation and second the time until total cessation of blood flow (occlusion time).
Statistical Analysis. Data were analyzed using Student t-test to compare normally distributed variables 
and Mann–Whitney U test when normal distribution was not given. All data are expressed as mean ± SEM. 
Differences were considered significant when the error probability was P < 0.05.
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